Quarterly Activities/Appendix 4C Cash Flow Report

• Zelira's HOPE® 1 SPV signed definitive agreements to raise US$32,981,075 (before costs)
• Zelira retains 39.70% interest in the HOPE® 1 SPV
• Funds will advance HOPE®'s accelerated regulatory pathway strategy utilizing the US FDA 505(b)(2) pathway

Zelira Therapeutics Ltd, a global leader in the development and commercialization of clinically validated cannabinoid-based medicines, has announced a transformative US$32,981,075 (before costs) fundraising into its HOPE® 1 SPV. The capital raising values Zelira's HOPE 1® SPV at a post-money valuation of US$65,962,150, with Zelira retaining a 39.70% interest. The funds will be used to advance HOPE®'s accelerated regulatory pathway strategy utilizing the United States' FDA 505(b)(2) pathway. In the near term, the SPV will focus on IND submission for HOPE® 1 to the FDA, initiation of the Phase 1 clinical trial, and filing for Orphan Drug Designation. Zelira and Thirdgate remain committed to closing the SPV Fundraising, which has been delayed due to factors beyond their control. Zelira's clinical validation and product development remain core to its growth plans, with FDA clinical trials planned for HOPE® 1 and the diabetic nerve drug treatment ZLT-L-007.

Zelira and Thirdgate remain committed to closing the SPV Fundraising. Zelira is focused on its clinical activities to develop and evaluate the efficacy, safety and tolerability of its proprietary formulations and products, with FDA clinical trials planned for HOPE® 1 and ZLT-L-007.